With patients of ovarian cancer as the target trial population, a clinical trial feasibility was performed. The clinical trial sites / investigators, who participated in this feasibility came mainly from India, Russia, Philippines, Vietnam, Thailand and South Korea.

Clinical Trial Details

  • Patient population included Ovarian cancer patients, whose disease has progressed or recurred after platinum-based chemotherapy and who are already receiving or scheduled to start therapy with Doxorubicin pegylated liposome intravenous injection
  • Patients who have a prior doxorubicin exposure that would result in a total lifetime exposure of 550 mg/ m2 or more after four cycles of treatment were excluded.
  • Trial design could be tailored without significant changes to meet USFDA guidance on Doxorubicin Liposome Injection In Vivo Bioequivalence Study.
  • While, the trial design suits USFDA submission requirements more closely, it could be utilized to target European / Thailand / India / other asian countries with suitable modifications.

Feasibility Results

While, clinical trial feasibility was primarily assessed with sites / investigators from India, an attempt was made to get feedback from sites / investigators from other potentially capable regions / countries. Here are the results of this feasibility.


Average Recruitment Rate Per Site Per Month









South Korea




Get Detailed Feasibility Report

Two options

  1. Just provide your email in the comments below and a report with further details will be sent to you. Don’t worry, your email will not be published or shared.
  2. Alternatively, click here to contact Credevo.